The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Preparing community centers for the administration of bispecific antibodies
In this video, Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly comments on practices for preparing community centers for the safe administration of bispecific antibodies. She highlights the feasibility of outpatient administration of these agents and the importance of educating the community about prophylactic measures to reduce the risk of cytokine release syndrome (CRS) and infection. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we are getting better. Many centers, and right now it’s still mostly academic centers, are doing bispecific antibodies as outpatient. So it shows you the feasibility of that. Many of us are using tocilizumab as prophylaxis to reduce the incidence of cytokine release. So again, making it safer. So helping the community adopt those practices, I think, is really the next important step...
So we are getting better. Many centers, and right now it’s still mostly academic centers, are doing bispecific antibodies as outpatient. So it shows you the feasibility of that. Many of us are using tocilizumab as prophylaxis to reduce the incidence of cytokine release. So again, making it safer. So helping the community adopt those practices, I think, is really the next important step. Their biggest challenge is really how do you manage CRS when it happens quickly, easily, and safely. So sort of demystifying that, I think, is also important. I think the other key to success with bispecifics is certainly in regards to infection prophylaxis, right? Because even in the trials where they’ve been moved earlier, there still is a signal of infections that tapers off, but clearly, understanding the use of IVIG, PGLP prophylaxis is all incredibly important for success.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
